While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Getting the Shingrix vaccine after the age of 50 can reduce your chances of developing the painful skin condition known as shingles. Vaccination also might help reduce your risk of dementia, according ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

This article discusses what you need to know about Shingrix, the shingles vaccine. Getting vaccinated is the best way to prevent shingles and postherpetic neuralgia (PHN). It’s estimated that up ...

Shingrix was hit hard in the first quarter as a result of the prioritisation of COVID-19 vaccination programmes in the US and other markets, with sales dropping almost 50% to £327 million, but ...

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

By age 50, VZV is present in most adults and may reactivate with advancing age. Shingrix is a non-live, recombinant subunit vaccine indicated to prevent shingles in adults 50 and over. It combines ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of ...